Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

President Donald Trump signed executive orders imposing tariffs on almost all imports from Canada, Mexico and China. Tariffs ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...